NEWS & EVENTS

Catalent today announced it will host a one day workshop titled, “Achieving Integrated Biologics Development: Challenges and How to Tackle Them”.

Catalent today announced the appointment of Jim Walter as Vice President of Operations for its Oral and Specialty Delivery business.

Catalent today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors.

Catalent, Inc. today announced that it had completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for innovators of advanced biotherapeutics.

Catalent today announced that it has been officially recognized by the Top Employers Institute as a Top Employer 2020 in the United States.

Catalent and MaSTherCell Global, Inc. today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for an aggregate of $315 million in cash.

Catalent today announced the appointment of Ricci Whitlow as President, Clinical Supply Services. Ms. Whitlow succeeds Paul Hegwood, who plans to retire in March 2020.

Catalent today welcomed the news that DiaMedica Therapeutics has received U.S. FDA approval to commence Phase 2 clinical trials of its lead candidate, DM199, for chronic kidney disease.

Catalent today announced that Christopher Hepler, Manager, Catalent Biologics Analytical Development, has been invited to speak on ways to improve assay development at the upcoming CASSS WCBP symposium, which will be held on Jan 28 – 30, 2020.